Drug intelligence / Profile preview

VXN-OTITIS

Development stage: Unknown
Lead developer: Vaxinano
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

**VXN-OTITIS** is a Vaxinano veterinary vaccine candidate for prevention of otitis in dogs. It is described as a nanoparticle-formulated, inactivated whole-pathogen vaccine using Vaxinano's STELLAR-NP platform; the specific pathogen antigen composition and route of administration have not been publicly disclosed. Vaxinano's veterinary pipeline lists the program at Phase 1, while another pipeline image lists it as preclinical.

Beyond the preview

Go deeper on VXN-OTITIS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXN-OTITIS.

Explore the full profile